Results 221 to 230 of about 23,474 (264)

T-VEC oncolytic viral therapy shows promise in melanoma

Nature Reviews Clinical Oncology, 2015
David Killock
exaly   +2 more sources

Talimogene Laherparepvec (T-VEC)

2021
Talimogene laherparepvec (T-VEC, IMLYGIC®) is the first approved oncolytic virotherapy for the treatment of patients with advanced melanoma. As the drug is administered intratumorally, it is mainly suitable for the treatment of (sub)cutaneous lesions.
Zdzienicki, Marcin, Rutkowski, Piotr, Mulder, Evalyn, J. Grunhagen, Dirk   +3 more
openaire   +1 more source

Is there still a role for talimogene laherparepvec (T-VEC) in advanced melanoma? An indirect efficacy comparison of T-VEC plus ipilimumab combination therapy versus T-VEC alone as salvage therapy in unresectable metastatic melanoma

Expert Opinion on Biological Therapy, 2021
Talimogene laherparepvec (T-VEC) improves overall survival (OS) in unresectable stage IIIB/C-IV melanoma T-VEC may have synergistic effects with CTLA-4 inhibitors In the absence of a trial comparing T-VEC and ipilimumab (T-VEC + IPI) to T-VEC, we applied a novel indirect comparison method using extrapolated OS curves to estimate OS outcomes in a ...
Mohammad Fazel, Neda AlRawashdh, Ahmad Alamer, Clara Curiel-Lewandrowski, Ivo Abraham   +4 more
openaire   +2 more sources

Re-introduction of T-VEC Monotherapy in Recurrent Melanoma is Effective

Journal of Immunotherapy, 2022
Talimogene laherparepvec (T-VEC) is a modified herpes simplex virus type 1, which can be administered intralesionally in patients with stage IIIB/C-IVM1a (American Joint Committee of Cancer; AJCC 7th edition) unresectable melanoma.
Viola, Franke, Emma H A, Stahlie, Bernies, van der Hiel, Bart A, van de Wiel, Michel W J M, Wouters, Winan J, van Houdt, Alexander C J, van Akkooi   +6 more
openaire   +2 more sources

Talimogene laherparepvec (T-VEC) as cancer immunotherapy

Drugs of Today, 2015
Talimogene laherparepvec (T-VEC) is the first-in-class oncolytic virus immunotherapy for the treatment of cancer and was generated from an attenuated, recombinant herpes simplex virus. T-VEC has demonstrated therapeutic activity in melanoma patients and is being tested in a number of other cancers alone and in combination with standard cancer ...
F J, Kohlhapp, A, Zloza, H L, Kaufman
openaire   +2 more sources

Addition of T-VEC to Neoadjuvant Chemotherapy Increases TNBC Response

Cancer Discovery, 2023
Abstract Neoadjuvant chemotherapy plus the oncolytic virus T-VEC had a pathologic complete response rate of 45.9%.
openaire   +1 more source

Oncolytic Viruses: T-VEC and Others

2017
Immunotherapy has become a standard for treatment of several advanced cancers such as melanoma, lung cancer, and head and neck cancer. Lymphocyte-rich tumor microenvironment is a predictor factor for response to immunotherapy. Although, theoretically, these tumor-infiltrating lymphocytes should be highly immunogenic, it has been shown that the tumor ...
Rutika Mehta, Igor Puzanov
openaire   +1 more source

Talimogene laherparepvec (T-Vec) for the treatment of melanoma and other cancers

Seminars in Oncology, 2016
Talimogene laherparepvec (T-Vec) is the first live virus to be approved by the US Food and Drug Administration for the treatment of cancer. This engineered version of herpes simplex virus type 1 (HSV-1) is the product of decades of preclinical work aimed at identifying and modifying aspects of the viral genome involved in virulence and immunogenicity ...
Claud, Grigg, Zoë, Blake, Robyn, Gartrell, Adrian, Sacher, Bret, Taback, Yvonne, Saenger   +5 more
openaire   +2 more sources

Economic evaluation of the combination of talimogene laherparepvec (T-vec) plus ipilimumab (T-vec+Ipi) versus ipilimumab (Ipi) in patients (pts) with advanced unresectable melanoma.

Journal of Clinical Oncology, 2018
e21545Background: A recent trial comparing T-vec+Ipi vs Ipi found no differential benefit in progression-free survival (PFS) (HR 0.83, 95%CI 0.56–1.23), but noted objective response rates (ORR) of ...
Abdulaali Almutairi, Nimer Alsaid, Mok Oh, Hani M. Babiker, Ali McBride, Ivo Abraham   +5 more
openaire   +1 more source

Response to the Rechallenge With Talimogene Laherparepvec (T-VEC) After Ipilimumab/Nivolumab Treatment in Patient With Cutaneous Malignant Melanoma Who Initially Had a Progression on T-VEC With Pembrolizumab

Journal of Immunotherapy, 2019
Talimogene laherparepvec (T-VEC) is approved for unresected stage III–IV malignant melanoma. T-VEC has a direct cytotoxic effect and enhances the antitumor immunity of host cells. Immune checkpoints inhibitors also enhance the immunity of host cells by increasing the recruitment of antigen-presenting cells or activation and restoration of T-cell ...
Muhammad Z, Afzal, Keisuke, Shirai
openaire   +2 more sources